دورية أكاديمية
Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
| العنوان: | Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? |
|---|---|
| المؤلفون: | Blum K; Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA, USA.; Division of Nutrigenomics, Geneus Health, LLC., San Antonio, TX, USA.; Division of Neuroscience & Addiction Research, Pathway Healthcare, LLc., Birmingham, AL, USA.; Division of Addiction Services, Dominion Diagnostics, LLC. North Kingstown, RI, USA.; Division of Nutrigenomic Research, Victory Nutrition International, Lederach, PA, USA., Gold M; Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo, USA., Modestino EJ; Department of Psychology, Curry College, Milton, MA, USA., Baron D; Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA, USA.; Division of Nutrigenomics, Geneus Health, LLC., San Antonio, TX, USA., Boyett B; Division of Neuroscience & Addiction Research, Pathway Healthcare, LLc., Birmingham, AL, USA., Siwicki D; Division of Nutrigenomics, Geneus Health, LLC., San Antonio, TX, USA., Lott L; Division of Nutrigenomics, Geneus Health, LLC., San Antonio, TX, USA., Podesta A; Department of psychiatry, Tulane University School of Medicine, New Orleans, LA, USA., Roy AK; Department of psychiatry, Tulane University School of Medicine, New Orleans, LA, USA., Hauser M; Division of Addiction Services, Dominion Diagnostics, LLC. North Kingstown, RI, USA., Downs BW; Division of Nutrigenomic Research, Victory Nutrition International, Lederach, PA, USA., Badgaiyan RD; Department of Psychiatry, Veterans Administration Hospital at San Antonio, San Antonio, TX, USA. |
| المصدر: | Journal of systems and integrative neuroscience [J Syst Integr Neurosci] 2018 May 03; Vol. 4. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Open Access Text Pvt. Ltd Country of Publication: England NLM ID: 101671495 Publication Model: Print Cited Medium: Print ISSN: 2059-9781 (Print) Linking ISSN: 20599781 NLM ISO Abbreviation: J Syst Integr Neurosci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Open Access Text Pvt. Ltd |
| مستخلص: | Prescriptions for Benzodiazepines (BZDs) have risen continually. According to national statistics, the combination of BZDs with opioids has increased since 1999. BZDs (sometimes called "benzos") work to calm or sedate a person by raising the level of the inhibitory neurotransmitter GABA in the brain. In terms of neurochemistry, BZDs act at the GABAA receptors to inhibit excitatory neurons, reducing VTA glutaminergic drive to reduce dopamine release at the Nucleus accumbens. Benzodiazepine Use Disorder (BUD) is very difficult to treat, partly because BZDs are used to reduce anxiety which paradoxically induces hypodopaminergia. Considering this, we are proposing a paradigm shift. Instead of simply targeting chloride channel direct GABAA receptors for replacement or substitution therapy, we propose the induction of dopamine homeostasis. Our rationale is supported by the well-established notion that the root cause of drug and non-drug addictions (i.e. Reward Deficiency Syndrome [RDS]), at least in adults, involve dopaminergic dysfunction and heightened stress. This proposition involves coupling the Genetic Addiction Risk Score (GARS) with a subsequent polymorphic matched genetic customized Pro-Dopamine Regulator known as KB220ZPBM (Precision Behavioral Management). Induction of dopamine homeostasis will be clinically beneficial in attempts to combat BUD for at least three reasons: 1) During detoxification of alcoholism, the potential induction of dopamine regulation reduces the need for BZDs; 2) A major reason for BZD abuse is because people want to achieve stress reduction and subsequently, the potential induction of dopamine regulation acts as an anti-stress factor; and 3) BUD and OUD are known to reduce resting state functional connectivity, and as such, potential induction of dopamine regulation enhances resting state functional connectivity. Future randomized placebo-controlled studies will investigate this forward thinking proposed novel modality. |
| References: | J Pharmacol Sci. 2006;100(5):471-86. (PMID: 16474201) Neuropsychopharmacology. 2001 Apr;24(4):410-9. (PMID: 11182536) Curr Opin Pharmacol. 2006 Feb;6(1):108-13. (PMID: 16376147) J Clin Psychopharmacol. 1989 Dec;9(6):412-6. (PMID: 2574193) Brain Res. 1989 Jan 9;476(2):377-81. (PMID: 2702475) Subst Use Misuse. 2017 Mar 21;52(4):535-547. (PMID: 28033474) Epilepsy Res. 2002 May;49(3):203-10. (PMID: 12076841) Subst Use Misuse. 1996 Jan;31(2):177-96. (PMID: 8834006) Clin Med Rev Case Rep. 2016;3(8):null. (PMID: 29034323) Eur J Pediatr. 1999 Sep;158(9):748-9. (PMID: 10485309) J Clin Psychopharmacol. 2010 Jun;30(3):290-3. (PMID: 20473065) J Syst Integr Neurosci. 2017 Nov 17;3(6):. (PMID: 30197787) J Addict Dis. 2008;27(3):37-48. (PMID: 18956528) PLoS One. 2017 Apr 26;12(4):e0174774. (PMID: 28445527) Curr Opin Pharmacol. 2005 Feb;5(1):47-52. (PMID: 15661625) Drug Alcohol Depend. 1993 Dec;34(1):67-70. (PMID: 7909749) CPQ Neurol Psychol. 2018;1(2):null. (PMID: 30957097) Ann Neurol. 1996 Jan;39(1):95-9. (PMID: 8572673) Pain Med. 2016 Jan;17(1):85-98. (PMID: 26333030) J Subst Abuse Treat. 1993 May-Jun;10(3):297-302. (PMID: 8100281) Prog Brain Res. 2016;224:155-73. (PMID: 26822358) BMC Psychiatry. 2011 May 19;11:90. (PMID: 21595945) Mol Pharmacol. 2001 May;59(5):1243-8. (PMID: 11306709) Glob J Addict Rehabil Med. 2017 Feb;1(2):null. (PMID: 29399668) J Neurochem. 1989 May;52(5):1655-8. (PMID: 2709017) Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4. (PMID: 30370423) Neuropharmacology. 1998;37(1):83-91. (PMID: 9680261) Psychopharmacology (Berl). 2016 Jan;233(2):163-86. (PMID: 26676983) Cell Mol Life Sci. 2003 Apr;60(4):742-50. (PMID: 12785720) Arch Gen Psychiatry. 1991 May;48(5):448-52. (PMID: 2021297) Hum Psychopharmacol. 2011 Aug;26(6):404-11. (PMID: 21823170) Postgrad Med. 2015 Mar;127(2):232-41. (PMID: 25526228) J Pharmacol Exp Ther. 2001 May;297(2):727-35. (PMID: 11303064) Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):131-7. (PMID: 16243418) Postgrad Med J. 1988;64 Suppl 2:40-4. (PMID: 2905797) J Clin Psychopharmacol. 1987 Feb;7(1):11-5. (PMID: 2880872) Am J Public Health. 2016 Apr;106(4):686-8. (PMID: 26890165) Behav Pharmacol. 2007 Sep;18(5-6):447-60. (PMID: 17762513) J Psychopharmacol. 2009 Jun;23(4):401-9. (PMID: 19164495) Neuropharmacology. 2009;56 Suppl 1:3-8. (PMID: 18617195) Am J Drug Alcohol Abuse. 1993;19(1):65-78. (PMID: 8438832) Trends Neurosci. 2011 Apr;34(4):188-97. (PMID: 21353710) Isr J Psychiatry Relat Sci. 2002;39(2):104-12. (PMID: 12227225) Psychopharmacology (Berl). 1999 Jan;141(1):1-5. (PMID: 9952057) Alcohol. 1988 Nov-Dec;5(6):481-93. (PMID: 3072969) J Clin Psychopharmacol. 2000 Aug;20(4):467-71. (PMID: 10917408) J Biol Chem. 1996 Mar 8;271(10):5768-76. (PMID: 8621444) Drug Alcohol Depend. 1993 May;32(3):257-66. (PMID: 8102331) Encephale. 1997 Jul-Aug;23(4):290-9. (PMID: 9417395) J Pharmacol Exp Ther. 2007 Aug;322(2):569-81. (PMID: 17510319) Alcohol. 2001 Feb;23(2):117-22. (PMID: 11331109) Int J Addict. 1988 Sep;23(9):991-8. (PMID: 2906910) Nat Neurosci. 2014 May;17(5):704-9. (PMID: 24705184) Nature. 1987 Jul 16-22;328(6127):221-7. (PMID: 3037384) Eur J Pharmacol. 1983 Nov 25;95(3-4):323-4. (PMID: 6317418) MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. (PMID: 26987082) Science. 2004 Mar 26;303(5666):2040-2. (PMID: 15044807) Drug Alcohol Depend. 1999 Jun 1;55(1-2):63-8. (PMID: 10402150) Neuroimage. 2012 Oct 1;62(4):2281-95. (PMID: 22326834) Br J Pharmacol. 2002 Jan;135(1):257-65. (PMID: 11786502) Biochem J. 1999 Sep 1;342 ( Pt 2):313-20. (PMID: 10455017) Experientia. 1976 Apr 15;32(4):493-5. (PMID: 944645) Brain Res Rev. 2009 Apr;60(1):149-70. (PMID: 19167425) Brain Connect. 2012;2(5):246-53. (PMID: 22957904) Psychopharmacology (Berl). 1995 Feb;117(4):424-9. (PMID: 7604143) J Clin Psychopharmacol. 1999 Aug;19(4):341-8. (PMID: 10440462) J Neurophysiol. 1987 Jan;57(1):201-17. (PMID: 3559672) Am J Drug Alcohol Abuse. 2016 May;42(3):333-40. (PMID: 26962719) Eur J Pharmacol. 1989 Jun 20;165(2-3):337-8. (PMID: 2776836) Addiction. 1999 Oct;94(10):1533-40. (PMID: 10790905) Drug Alcohol Depend. 2010 Dec 1;112(3):226-33. (PMID: 20708349) Drug Alcohol Depend. 1996 Oct;42(2):117-23. (PMID: 8889410) PLoS One. 2013 May 07;8(5):e62911. (PMID: 23667541) BMJ. 2015 Jun 10;350:h2698. (PMID: 26063215) Experientia. 1976 Jan 15;32(1):79-82. (PMID: 942927) Arch Intern Med. 2011 Apr 11;171(7):686-91. (PMID: 21482846) BMJ. 2017 Mar 14;356:j760. (PMID: 28292769) Neurosci Lett. 1999 Nov 5;275(1):69-72. (PMID: 10554987) Nature. 1996 Feb 1;379(6564):449-51. (PMID: 8559249) J Addict Res Ther. 2012 Nov 27;3(5):139. (PMID: 23926462) Theor Biol Med Model. 2008 Nov 12;5:24. (PMID: 19014506) Epilepsy Res. 1998 Feb;29(3):233-49. (PMID: 9551785) Neuropsychopharmacology. 2003 Jan;28(1):63-72. (PMID: 12496941) Front Psychiatry. 2018 Nov 27;9:548. (PMID: 30542299) Am J Psychiatry. 2000 Jan;157(1):151. (PMID: 10618048) |
| معلومات مُعتمدة: | I01 CX000479 United States CX CSRD VA |
| فهرسة مساهمة: | Keywords: benzodiazepine use disorder; benzodiazepines; dopamine homeostasis; dopaminergic; gars; kb220; reward deficiency syndrome |
| تواريخ الأحداث: | Date Created: 20191122 Latest Revision: 20200928 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6865059 |
| DOI: | 10.15761/JSIN.1000196 |
| PMID: | 31750006 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2059-9781 |
|---|---|
| DOI: | 10.15761/JSIN.1000196 |